166 related articles for article (PubMed ID: 26231040)
1. Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Evans B; Griner E;
Elife; 2015 Jul; 4():e07420. PubMed ID: 26231040
[TBL] [Abstract][Full Text] [Related]
2. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Fiehn O; Showalter MR; Schaner-Tooley CE; ;
Elife; 2016 Feb; 5():. PubMed ID: 26943899
[TBL] [Abstract][Full Text] [Related]
3. Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Richarson AD; Scott DA; Zagnitko O; Aza-Blanc P; Chang CC; Russler-Germain DA;
Elife; 2016 Mar; 5():e10860. PubMed ID: 26971564
[TBL] [Abstract][Full Text] [Related]
4. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
5. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
Elife; 2017 Jun; 6():. PubMed ID: 28653623
[TBL] [Abstract][Full Text] [Related]
6. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.
Phelps M; Coss C; Wang H; Cook M; ;
Elife; 2016 Mar; 5():. PubMed ID: 26943900
[TBL] [Abstract][Full Text] [Related]
7. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
[TBL] [Abstract][Full Text] [Related]
8. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
9. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Sharma V; Young L; Cavadas M; Owen K;
Elife; 2016 Mar; 5():. PubMed ID: 26999821
[TBL] [Abstract][Full Text] [Related]
10. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
Khan I; Kerwin J; Owen K; Griner E; ;
Elife; 2015 Sep; 4():. PubMed ID: 26335297
[TBL] [Abstract][Full Text] [Related]
11. Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers.
Sharma V; Young L; Allison AB; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26894955
[TBL] [Abstract][Full Text] [Related]
12. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.
Fung JJ; Kosaka A; Shan X; Danet-Desnoyers G; Gormally M; Owen K; ;
Elife; 2015 Sep; 4():. PubMed ID: 26327698
[TBL] [Abstract][Full Text] [Related]
13. Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
Fiering S; Ang LH; Lacoste J; Smith TD; Griner E;
Elife; 2015 Jul; 4():e04796. PubMed ID: 26179155
[TBL] [Abstract][Full Text] [Related]
14. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Haven B; Heilig E; Donham C; Settles M; Vasilevsky N; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26905833
[TBL] [Abstract][Full Text] [Related]
15. Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.
Peng S; Chen H; Chen L; Yang G; Liu J; Cheng X; Tang Y
Chem Res Toxicol; 2022 Feb; 35(2):115-124. PubMed ID: 35018778
[TBL] [Abstract][Full Text] [Related]
16. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Vanden Heuvel JP; Bullenkamp J;
Elife; 2016 Jun; 5():. PubMed ID: 27336789
[TBL] [Abstract][Full Text] [Related]
17. Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Bhargava A; Pelech S; Woodard B; Kerwin J; Maherali N; ;
Elife; 2016 Feb; 5():. PubMed ID: 26882073
[TBL] [Abstract][Full Text] [Related]
18. Registered report: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Lesnik J; Antes T; Kim J; Griner E; Pedro L; ;
Elife; 2016 Jan; 5():e07383. PubMed ID: 26826285
[TBL] [Abstract][Full Text] [Related]
19. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
Evans J; Essex A; Xin H; Amitai N; Brinton L; Griner E; ;
Elife; 2015 Aug; 4():. PubMed ID: 26287525
[TBL] [Abstract][Full Text] [Related]
20. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
